Targeting cellular heterogeneity with CXCR2 blockade for the treatment of therapy-resistant prostate cancer.

doi:10.1126/scitranslmed.aax0428

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Targeting cellular heterogeneity with CXCR2 blockade for the treatment of therapy-resistant prostate cancer.

Science translational medicine - 4 Dec 2019

Li Yanjing, He Yiping, Butler William, Xu Lingfan, Chang Yan, Lei Kefeng, Zhang Hong, Zhou Yinglu, Gao Allen C, Zhang Qingfu, Taylor Daniel G, Cheng Donghui, Farber-Katz Suzette, Karam Rachid, Landrith Tyler, Li Bing, Wu Sitao, Hsuan Vickie, Yang Qing, Hu Hailiang, Chen Xufeng, Flowers Melissa, McCall Shannon J, Lee John K, Smith Bryan A, Park Jung Wook, Goldstein Andrew S, Witte Owen N, Wang Qianben, Rettig Matthew B, Armstrong Andrew J, Cheng Qing, Huang Jiaoti

Abstract excerpt

Hormonal therapy targeting androgen receptor (AR) is initially effective to treat prostate cancer (PCa), but it eventually fails. It has been hypothesized that cellular heterogeneity of PCa, consisting of AR+ luminal tumor cells and AR- neuroendocrine (NE) tumor cells, may contribute to therapy failure. Here, we describe the successful purification of NE cells from primary fresh human prostate adenocarcinoma...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Mice, Nude

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neoplasm Grading

Share to Neoplastic Stem Cells

Share to Neovascularization, Pathologic

Share to Neuroendocrine Tumors

Share to Neurosecretory Systems

Share to Receptors, Interleukin-8B

Share to Tumor Microenvironment

Source

Open in PubMed Open full text

Identifiers

PMID: 31801883
DOI: 10.1126/scitranslmed.aax0428
PMCID: PMC7238624

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting cellular heterogeneity with CXCR2 blockade for the treatment of therapy-resistant prostate cancer.PMID 31801883Read ↗

Androgen receptor (AR) heterogeneity in prostate cancer and therapy resistanceSemantic proximity Read ↗

Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responsesSemantic proximity Read ↗

Androgen receptor and prostate cancer stem cells: biological mechanisms and clinical implications.Semantic proximity Read ↗

Trop2 is a driver of metastatic prostate cancer with neuroendocrine phenotype via PARP1.Semantic proximity Read ↗

Reduced NCOR2 expression accelerates androgen deprivation therapy failure in prostate cancerSemantic proximity Read ↗

Localized high-risk prostate cancer harbors an androgen receptor low subpopulation susceptible to HER2 inhibitionSemantic proximity Read ↗

Inhibition of FOXC2 restores epithelial phenotype and drug sensitivity in prostate cancer cells with stem-cell properties.Semantic proximity Read ↗

Cell-resolved high-dimensional imaging analysis, therapeutic modeling, and a Phase Ib clinical study establish BCL-2 as a target across heterogeneous CRPC subtypesSemantic proximity Read ↗

BCL2 expression is enriched in advanced prostate cancer with features of lineage plasticitySemantic proximity Read ↗

Neuropilin-2 axis in regulating secretory phenotype of neuroendocrine-like prostate cancer cells and its implication in therapy resistance.Semantic proximity Read ↗

Resistance to androgen receptor signaling inhibition does not necessitate development of neuroendocrine prostate cancerSemantic proximity Read ↗

Circulating tumor cells exhibit a biologically aggressive cancer phenotype accompanied by selective resistance to chemotherapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.